Denosumab for Muscle Health in Older Adults with Osteoporosis

This study is looking at whether Denosumab, a medication approved for osteoporosis (weak bones), can help improve or keep muscle strength and function in older adults. You might be able to join if you are 65 or older, live in a nursing home, assisted living, or senior community, and have osteoporosis or low bone mass. Participants will receive either Denosumab or Zoledronic Acid (another osteoporosis medication). Researchers will measure changes in knee strength after 12 months to see if Denosumab is effective. The current status of this study is unclear, and it plans to enroll 155 people.

Study design
This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 155 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 12 months, suggesting participants will be followed for at least this long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06118905

Preserving Geriatric Muscle With an Osteoporosis Medication

Recruiting
PHASE4Ages 65+InterventionalTreatment
Susan L. Greenspan
~155 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:Denosumab 60 MG/MLZoledronic Acid 5Mg/Bag 100Ml Infusion

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Knee extension strength change
Measured over 12 Months
Osteoporosis
1 sites across 1 states
Pennsylvania1

Opens a ready-to-send draft in your own email app — review before sending.

  • Knee extension strength change12 Months

    The primary muscle strength outcome measure will be the peak muscle force generated by the dominant leg (same side as dominant hand) knee extensor muscles in the sitting position with the knee at 60 degrees of flexion.